Skip to main content

04-05-2018 | Rheumatology | News | Article

BSR 2018 in brief

Predictors of JIA remission vary according to treatment target

This information is brought to you by medwireNews and is not sponsored by, nor a part of, the British Society for Rheumatology.

medwireNews: Research suggests that factors predicting remission in patients with juvenile idiopathic arthritis (JIA) vary according to the score used to define remission.

Stephanie Shoop-Worrall (University of Manchester, UK) and colleagues observed that of 1045 children with JIA who were enrolled in the Childhood Arthritis Prospective Study, 18% achieved remission according to the Wallace criteria at 3 years of follow-up, while 30% achieved remission as defined by the clinical Juvenile Arthritis Disease Activity Score (cJADAS).

In a multivariable logistic regression analysis, improvements in the number of active joints, physician and parent global assessments, and erythrocyte sedimentation rate (ESR) within the first year of treatment were identified as significant predictors of 3-year remission according to the Wallace criteria among patients with oligoarthritis.

On the other hand, for remission defined by cJADAS, all but one of the factors studied – including active and limited joint counts, physician and parent global assessments, and pain – were significantly associated with remission. ESR was not associated with cJADAS remission.

The researchers observed largely similar results for patients with polyarthritis, but improvement in limited joint counts, rather than active joint counts, was significantly associated with remission according to the Wallace criteria.

These findings indicate that “overall changes in disease activity and well-being predict both states of remission,” but “depending on which treatment target is in use, there may be different predictors of disease state,” said Shoop-Worrall.

The results were presented at the 2018 British Society for Rheumatology Annual Conference in Liverpool, UK.

By Claire Barnard

medwireNews is an independent medical news service provided by Springer Healthcare. © 2018 Springer Healthcare part of the Springer Nature group